Yifan Pharmaceutical - Public Comps and Valuation Multiples

Yifan Pharmaceutical Overview

About Yifan Pharmaceutical

Yifan Pharmaceutical Co Ltd is a China-based company engaged in R&D and production company focusing on the pharmaceutical and health sectors. Its vision is to develop drugs with definite clinical values, to help disease-afflicted patients regain health. The group focuses on four business areas such as biologics, small molecules, synthetic biologics, and special traditional Chinese medicines (TCMs). The products of the company are Ryzneuta, Plerixafor Injection, Vincristine Sulfate, Skin Allergy Reli, and Others.

Founded

1994

HQ

Employees

1.5K+

Website

en.yifanyy.com

Sectors

Biopharmaceuticals
Small Molecules
Drug Development & Therapeutics
BioTech
DeepTech

Financials

LTM Revenue $815M

LTM EBITDA $166M

EV

$2.6B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Yifan Pharmaceutical Financials

As of September 2025, Yifan Pharmaceutical reported last 12-month revenue of $815M and EBITDA of $166M.

In the same period, Yifan Pharmaceutical generated $409M in LTM gross profit and $78.2M in net income.

See Yifan Pharmaceutical valuation multiples based on analyst estimates

Yifan Pharmaceutical P&L

In the most recent fiscal year, Yifan Pharmaceutical reported revenue of $724M and EBITDA of $111M.

Yifan Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Yifan Pharmaceutical valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$815M	XXX	$724M	XXX	XXX	XXX
Gross Profit	$409M	XXX	$343M	XXX	XXX	XXX
Gross Margin	50%	XXX	47%	XXX	XXX	XXX
EBITDA	$166M	XXX	$111M	XXX	XXX	XXX
EBITDA Margin	20%	XXX	15%	XXX	XXX	XXX
EBIT	$79.4M	XXX	$84.8M	XXX	XXX	XXX
EBIT Margin	10%	XXX	12%	XXX	XXX	XXX
Net Profit	$78.2M	XXX	$54.1M	XXX	XXX	XXX
Net Margin	10%	XXX	7%	XXX	XXX	XXX
Net Debt	XXX	XXX	$112M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Yifan Pharmaceutical including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $815M. EBITDA for the last twelve months was $166M. In the most recent fiscal year, Yifan Pharmaceutical achieved $724M in revenue and $111M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$815M	Analyst estimates available to subscribers	$724M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$409M	Analyst estimates available to subscribers	$343M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	50.2% gross margin	Analyst estimates available to subscribers	47.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$166M	Analyst estimates available to subscribers	$111M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	20.4% EBITDA margin	Analyst estimates available to subscribers	15.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$79.4M	Analyst estimates available to subscribers	$84.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	9.7% EBIT margin	Analyst estimates available to subscribers	11.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$78.2M	Analyst estimates available to subscribers	$54.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	9.6% net profit margin	Analyst estimates available to subscribers	7.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$112M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Yifan Pharmaceutical

This financial data table provides comprehensive performance metrics for Yifan Pharmaceutical, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Yifan Pharmaceutical generated $815M in revenue over the last twelve months.
The company achieved $166M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $409M.
Net income over the last twelve months reached $78.2M.

Fiscal Year Performance

In the most recent fiscal year, Yifan Pharmaceutical reported $724M in total revenue.
Fiscal year EBITDA was $111M.
The company maintained a gross profit margin of 47.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was 15.4%.
Net profit margin reached 7.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Yifan Pharmaceutical. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Yifan Pharmaceutical Stock Performance

Yifan Pharmaceutical has current market cap of CNY 17.0B (or $2.4B), and EV of CNY 18.5B (or $2.6B).

Market Cap Evolution

Yifan Pharmaceutical Stock Data

As of October 17, 2025, Yifan Pharmaceutical's stock price is CNY 14 (or $2).

See Yifan Pharmaceutical trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.6B	$2.4B	XXX	XXX	XXX	XXX	$0.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Yifan Pharmaceutical Valuation Multiples

Yifan Pharmaceutical's trades at 3.6x EV/Revenue multiple, and 23.3x EV/EBITDA.

See valuation multiples for Yifan Pharmaceutical and 15K+ public comps

Yifan Pharmaceutical Financial Valuation Multiples

As of October 17, 2025, Yifan Pharmaceutical has market cap of $2.4B and EV of $2.6B.

Equity research analysts estimate Yifan Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Yifan Pharmaceutical has a P/E ratio of 30.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.4B	XXX	$2.4B	XXX	XXX	XXX
EV (current)	$2.6B	XXX	$2.6B	XXX	XXX	XXX
EV/Revenue	3.2x	XXX	3.6x	XXX	XXX	XXX
EV/EBITDA	15.6x	XXX	23.3x	XXX	XXX	XXX
EV/EBIT	32.7x	XXX	30.6x	XXX	XXX	XXX
EV/Gross Profit	6.3x	XXX	n/a	XXX	XXX	XXX
P/E	30.5x	XXX	44.1x	XXX	XXX	XXX
EV/FCF	n/a	XXX	1472.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Yifan Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Yifan Pharmaceutical Margins & Growth Rates

Yifan Pharmaceutical's last 12 month revenue growth is 15%

Yifan Pharmaceutical's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.

Yifan Pharmaceutical's rule of 40 is 2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Yifan Pharmaceutical's rule of X is 58% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Yifan Pharmaceutical and other 15K+ public comps

Yifan Pharmaceutical Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	15%	XXX	15%	XXX	XXX	XXX
EBITDA Margin	20%	XXX	15%	XXX	XXX	XXX
EBITDA Growth	19%	XXX	n/a	XXX	XXX	XXX
Rule of 40	2%	XXX	30%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	58%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.5M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	19%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	6%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	36%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial